Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2023 - 01 - 05 tags : Therapeutics save search
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
Published: 2023-01-05 (Crawled : 23:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: -60.18%
H: 3.88%
C: -3.2%
collaboration therapeutics agreement
Pittsburgh's Carmell Therapeutics is going public via SPAC – Technical.ly
Published: 2023-01-05 (Crawled : 21:00) - spacfeed.com
ATLXD | $8.1 0
|
n/a
|
| O: -0.18%
H: 8.6%
C: 8.6%
LTUM | $0.0364 33.16% 230K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 5.0%
C: 1.89%
therapeutics spac
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
Published: 2023-01-05 (Crawled : 20:00) - biospace.com/
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -0.44%
H: 10.21%
C: 10.21%
disease diagnostic therapeutics update platform
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
Published: 2023-01-05 (Crawled : 19:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
medical therapeutics
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
Published: 2023-01-05 (Crawled : 19:00) - biospace.com/
ALGS | $0.735 -7.33% -7.9% 140K
|
Health Technology
|
| O: 2.13%
H: 7.29%
C: 3.13%
alg-0550 drug candidate therapeutics
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 TrialA Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options
Published: 2023-01-05 (Crawled : 17:00) - biospace.com/
OVID | $3.245 1.09% 1.08% 180K
|
Health Technology
|
| O: -1.05%
H: 2.13%
C: 2.13%
ov329 treatment rare therapeutics phase 1
ZyVersa Therapeutics Appoints Three New Board Members
Published: 2023-01-05 (Crawled : 15:00) - prnewswire.com
FWBI | $2.59 -8.8% -9.65% 83K
|
Manufacturing
|
| O: 1.82%
H: 14.29%
C: 2.68%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.8%
H: 0.52%
C: -0.14%
AXGN | $6.51 -0.61% -0.61% 330K
|
Health Technology
|
| O: -1.33%
H: 7.56%
C: 6.95%
therapeutics
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
Published: 2023-01-05 (Crawled : 14:20) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 5.22%
H: 0.58%
C: -0.35%
acer-801 trials therapeutics
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
Published: 2023-01-05 (Crawled : 14:00) - biospace.com/
TEX | $60.25 0.8% 0.0% 870K
|
Producer Manufacturing
|
| O: -0.45%
H: 0.94%
C: -0.49%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.87%
H: 0.31%
C: 0.02%
OZK | $44.93 2.58% 2.52% 1.6M
|
Finance
|
| O: -0.75%
H: 0.13%
C: -1.84%
therapeutics financial
TCR² Therapeutics Announces Pipeline Priorities for 2023
Published: 2023-01-05 (Crawled : 14:00) - globenewswire.com
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
therapeutics
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
Published: 2023-01-05 (Crawled : 13:20) - globenewswire.com
OVID | $3.245 1.09% 1.08% 180K
|
Health Technology
|
| O: -1.05%
H: 2.13%
C: 2.13%
ov329 trial therapeutics phase 1
Vivos Therapeutics Announces Pricing of $8 Million Private Placement
Published: 2023-01-05 (Crawled : 13:20) - globenewswire.com
VVOS | $2.72 2.26% 2.21% 34K
|
Health Technology
|
| O: -15.96%
H: 42.41%
C: 18.99%
therapeutics
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: -2.55%
ser-155 genomic therapeutics study phase 2b
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.25%
H: 0.81%
C: -0.13%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -1.3%
H: 2.05%
C: 0.44%
therapeutics
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
SMMT A | $3.51 0.0% 1.7M
|
Health Technology
|
| O: -1.85%
H: 6.03%
C: -7.91%
conference therapeutics
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023
Published: 2023-01-05 (Crawled : 13:00) - prnewswire.com
BCLI | $0.5384 4.69% 4.48% 1M
|
Health Technology
|
| O: 0.61%
H: 3.66%
C: -6.1%
biotech therapeutics
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Published: 2023-01-05 (Crawled : 12:20) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 33.65%
H: 4.61%
C: -8.47%
otl-203 fda clearance application therapeutics mps-ih mps-i
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
Published: 2023-01-05 (Crawled : 12:20) - biospace.com/
CYBN | News | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 5.26%
H: 8.21%
C: 3.15%
treatment trial therapeutics psilocybin
Caris Life Sciences Announces the Expansion of Caris Discovery to Accelerate Development of Novel Precision Therapeutics to Combat Cancer
Published: 2023-01-05 (Crawled : 12:00) - prnewswire.com
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.27%
H: 1.53%
C: 1.12%
expansion sciences life therapeutics cancer
PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics
Published: 2023-01-05 (Crawled : 09:00) - prnewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 1.45%
H: 2.57%
C: -0.57%
license therapeutics agreement
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.